Abstract:Objective Durable hepatitis B virus (HBV)DNA suppression is important to antiviral effectiveness in chronic hepatitis B (CHB). In this study,we analyzed the long-term efficacy and resistance profile of entecavir (ETV) monotherapy in 20 Chinese patients with nucleoside nave CHB treated for at least 5 years. Methods Twenty HBeAg positive patients with HBV DNA level 107 copies/mL and alanine aminotransferase (ALT)level 2-fold upper limit of normal (ULN)received ETV 0.5 or 1 mg/day for accumulated 5 years. Serum HBV DNA level,HBeAg status and HBsAg level were assessed at baseline and at year 1 ,2 ,3 ,4 and 5 . Gene sequencing was also conducted in the patients whose serum HBV DNA level > 300 copies/mL at year 5 . Results The ratio of HBV DNA undetectable (<300 copies/mL)for these 20 patients were 60% ,40% ,50% ,85% and 85% at year 1,2,3,4 and 5 respectively. The ratios of HBeAg loss were 15% ,15% ,20% ,30% and 65% at year 1,2,3,4 and 5,respectively. Three of 20 patients (15% )achieved HBeAgseroconversion at year 4 and 5 . Variables were compared between the patients whose serum HBV DNA < 300 copies/mL and those of patients > 300 copies/mL at week 48. Virological response rate was 100% and 66.7% at week 240 in the former's and the latter's,respectively;HBeAg seroconversion rate was 27.3% and 0 at week 240 in the former's and latter's, respectively. Virological response rate was 100% at week 240 in the patients whose ALT level 2-fold ULN,and was only 75% in the patients whose ALT level < 2-fold ULN;Meanwhile,the rate of HBeAg seroconversion was 37.5% and 0 in the former's and latter's. The rate of HBeAg seroconversion was 1 1 .1% at week 240 in the patients whose HBV DNA level>108 copies/mL at baseline,and was only 50% in the patients whose HBV DNA level <108 copies/mL at baseline,the statistics had significant difference (P<0.05). The mean serum HBsAg levels of the patients were (4.04±0.40)log10 IU/mL,(3.64±0.44)log10 IU/mL,(3.73±0.41)log10 IU/mL,(3.53±0.55)log10 IU/mL,(3.55±0.55)log10 IU/mL and (3.55±0.63)log10 IU/mL at baseline and at year 1,2,3,4 and 5,respectively. HBsAg levels had a greater mean reduction at year 1 (P= 0.005),3 (P= 0.005),4 (P= 0.009)and 5 (P= 0.018)compared with baseline, respectively. The HBsAg titers at baseline were significantly different between the patients whose HBeAg loss (3.95 ± 0.54)log10 IU/mL and HBeAg non-loss (4.20±0.48)log10 IU/mL at week 240 (P= 0.005). Non adverse effect was observed in this study. Conclusion These analysis demonstrates that long-term treatment of ETV monotherapy is effective in maintaining viral suppression. No ETV resistance substitution are detected in these patients.

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Correlation Between Serum Entecavir Concentration And Virological Response In Patients With Chronic Type B Hepatitis

Incidence and Resolution of Steatohepatitis in Patients Receiving Entecavir for Chronic Hepatitis B

Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48

Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China.

Therapeutic efficacy and related factors of entecavir treatment for patients with acute on chronic hepatitis B liver failure

Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism

Association between nonalcoholic fatty liver disease status changes and antiviral efficacy in chronic hepatitis B

Virological, Serological and Biochemical Outcomes Through 3 Years of Entecavir Treatment in Nucleoside-Naive Chinese Chronic Hepatitis B Patients

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment

Clinical efficacy of traditional Chinese medicine combined with entecavir in chronic hepatitis B patients

[Impact of Liver Steatosis on Antiviral Effects of Pegylated Interferon-Alpha in Patients with Chronic Hepatitis B].

Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B

Long term efficacy of entecavir therapy on viral suppression in nucleoside-nave chronic hepatitis B patients

High Value of Controlled Attenuation Parameter Predicts A Poor Antiviral Response in Patients with Chronic Hepatits B